AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29193877 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo) for 10 days
Number of subjects: 80
Study 26525804 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotational atherectomy (RA) followed by stenting
Number of subjects: 240
Study 26525804 — intervention group
Group type: COMPARATOR
Intervention: Stenting without RA (control)
Number of subjects: 240
Study 25019115 — intervention group
Group type: EXPERIMENTAL
Intervention: Honey applied four times a day for 5 days
Number of subjects: 94
Study 25019115 — intervention group
Group type: COMPARATOR
Intervention: Topical corticosteroid
Number of subjects: 94
Study 25019115 — intervention group
Group type: COMPARATOR
Intervention: Orabase treatment
Number of subjects: 94
Study 23449351 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX/XELOX plus cediranib 20 mg (HORIZON II)
Number of subjects: 2000
Study 23449351 — intervention group
Group type: EXPERIMENTAL
Intervention: mFOLFOX6 plus cediranib 20 mg (HORIZON III)
Number of subjects: 2000
Study 23449351 — intervention group
Group type: COMPARATOR
Intervention: Placebo (HORIZON II)
Number of subjects: 2000
Study 23449351 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab (HORIZON III)
Number of subjects: 2000
Study 19898259 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel/cisplatin/fluorouracil (TPF) combination chemotherapy
Number of subjects: 39
Study 18375612 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO)
Number of subjects: 108
Study 18375612 — intervention group
Group type: COMPARATOR
Intervention: No inhaled nitric oxide (no iNO)
Number of subjects: 108
Study 17045905 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 g walnuts
Number of subjects: 24
Study 17045905 — intervention group
Group type: COMPARATOR
Intervention: 25 g olive oil
Number of subjects: 24
Study 12781165 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure group (daily tasting of the target vegetable for 14 days)
Number of subjects: 156
Study 12781165 — intervention group
Group type: COMPARATOR
Intervention: Information group (nutritional advice and leaflet)
Number of subjects: 156
Study 12781165 — intervention group
Group type: COMPARATOR
Intervention: Control group (no further intervention)
Number of subjects: 156
Study 11220442 — intervention group
Group type: EXPERIMENTAL
Intervention: Covariational causes
Number of subjects: 0
Study 11220442 — intervention group
Group type: COMPARATOR
Intervention: Goal-based causes
Number of subjects: 0
Study 9863110 — intervention group
Group type: EXPERIMENTAL
Intervention: Xiaoliu Tablet (XLT)
Number of subjects: 71
Study 9863110 — intervention group
Group type: COMPARATOR
Intervention: Normal women
Number of subjects: 71
Study 8306925 — intervention group
Group type: EXPERIMENTAL
Intervention: haloperidol (40 mg a day) + carbamazepine (400 mg a day)
Number of subjects: 24
Study 8306925 — intervention group
Group type: EXPERIMENTAL
Intervention: haloperidol (40 mg a day) + bromocriptine (2.5 mg a day)
Number of subjects: 24
Study 8306925 — intervention group
Group type: EXPERIMENTAL
Intervention: haloperidol (40 mg a day) + cyproheptadine (24 mg a day)
Number of subjects: 24
Study 8306925 — intervention group
Group type: COMPARATOR
Intervention: haloperidol (40 mg a day) + placebo
Number of subjects: 24
Study 3521475 — intervention group
Group type: EXPERIMENTAL
Intervention: Azlocillin plus amikacin
Number of subjects: 742
Study 3521475 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime plus amikacin
Number of subjects: 742
Study 3521475 — intervention group
Group type: COMPARATOR
Intervention: Ticarcillin plus amikacin
Number of subjects: 742
Study 3521475 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with gram-negative rod bacteremias and profound granulocytopenia
Number of subjects: 742
Study 3521475 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with rising granulocyte counts
Number of subjects: 742
Study 30146495 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole (5 mg uncoated tablets)
Number of subjects: 30
Study 30146495 — intervention group
Group type: COMPARATOR
Intervention: Lithium carbonate (300 mg uncoated tablets)
Number of subjects: 30
Study 26988025 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconia abutments
Number of subjects: 56
Study 26988025 — intervention group
Group type: COMPARATOR
Intervention: Titanium abutments
Number of subjects: 56
Study 26988025 — intervention group
Group type: COMPARATOR
Intervention: Titanium nitride abutments
Number of subjects: 56
Study 24387003 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU)
Number of subjects: 17
Study 24387003 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (48 IU)
Number of subjects: 17
Study 24387003 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 22281801 — intervention group
Group type: EXPERIMENTAL
Intervention: Auto-servoventilation (ASV)
Number of subjects: 70
Study 22281801 — intervention group
Group type: COMPARATOR
Intervention: Continuous positive airway pressure (CPAP)
Number of subjects: 70
Study 22281801 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ASV and CPAP
Number of subjects: 70
Study 20369701 — intervention group
Group type: EXPERIMENTAL
Intervention: Spermatic vein and artery ligation (n = 46)
Number of subjects: 88
Study 20369701 — intervention group
Group type: COMPARATOR
Intervention: Spermatic vein and artery preservation (n = 42)
Number of subjects: 88
Study 18491670 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin‐modified glass ionomer cement (RMGIC)
Number of subjects: 45
Study 18491670 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyacid‐modified resin composite (PMC)
Number of subjects: 45
Study 18491670 — intervention group
Group type: EXPERIMENTAL
Intervention: High viscosity GIC (HVGIC)
Number of subjects: 45
Study 18491670 — intervention group
Group type: COMPARATOR
Intervention: Amalgam (Amlg)
Number of subjects: 45
Study 15941800 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid preventive therapy (300 mg/d for 6 months)
Number of subjects: 1655
Study 15941800 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic enrollment
Number of subjects: 1655
Study 15941800 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic enrollment (excluding individuals with a history of tuberculosis)
Number of subjects: 1655
Study 12638100 — intervention group
Group type: EXPERIMENTAL
Intervention: Heatwrap therapy
Number of subjects: 76
Study 10842858 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected individuals
Number of subjects: 28
Study 10842858 — intervention group
Group type: COMPARATOR
Intervention: Noninfected control subjects
Number of subjects: 28
Study 8983316 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac resinate 75mg taken once or twice daily
Number of subjects: 216
Study 8983316 — intervention group
Group type: COMPARATOR
Intervention: Conventional enteric‐coated diclofenac sodium 50mg tablets given two or three times daily
Number of subjects: 216
Study 1931143 — intervention group
Group type: EXPERIMENTAL
Intervention: Active aspirin and active beta-carotene
Number of subjects: 22071
Study 1931143 — intervention group
Group type: EXPERIMENTAL
Intervention: Active aspirin and beta-carotene placebo
Number of subjects: 22071
Study 1931143 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin placebo and active beta-carotene
Number of subjects: 22071
Study 1931143 — intervention group
Group type: COMPARATOR
Intervention: Both placebos
Number of subjects: 22071
Study 7180622 — intervention group
Group type: EXPERIMENTAL
Intervention: 6, 12 or 24 hours of sensory deprivation
Number of subjects: 72
Study 7180622 — intervention group
Group type: COMPARATOR
Intervention: 24 hours of social isolation
Number of subjects: 72
Study 30569416 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser helmet (RAMACAP)
Number of subjects: 40
Study 30569416 — intervention group
Group type: COMPARATOR
Intervention: Sham helmet
Number of subjects: 40
Study 28183702 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals with diabetes mellitus (HbA1c levels)
Number of subjects: 319
Study 28183702 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals without diabetes mellitus (HbA1c levels)
Number of subjects: 319
Study 28183702 — intervention group
Group type: EXPERIMENTAL
Intervention: Total study population (HbA1c levels)
Number of subjects: 319
Study 28183702 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest HbA1c tertile
Number of subjects: 319
Study 28183702 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals without self-reported diabetes mellitus
Number of subjects: 319
Study 25801942 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (doses: 6, 12, 18, 24, 30, and 42 g)
Number of subjects: 24
Study 25801942 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 25801942 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol
Number of subjects: 24
Study 23688259 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal dietary and physical activity counselling
Number of subjects: 185
Study 23688259 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 185
Study 21385352 — intervention group
Group type: EXPERIMENTAL
Intervention: Ward-based pharmacy care from the clinical pharmacy team, including medication reconciliation at admission, daily medication review, and patient counselling at discharge.
Number of subjects: 0
Study 21385352 — intervention group
Group type: COMPARATOR
Intervention: Standard pharmaceutical care (Control group).
Number of subjects: 0
Study 21385352 — intervention group
Group type: EXPERIMENTAL
Intervention: Ward-based pharmacy care.
Number of subjects: 0
Study 19107948 — intervention group
Group type: EXPERIMENTAL
Intervention: Submandibular salivary gland transfer (SGT)
Number of subjects: 120
Study 19107948 — intervention group
Group type: COMPARATOR
Intervention: Pilocarpine
Number of subjects: 120
Study 17405999 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg orally twice daily
Number of subjects: 100
Study 17405999 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 12684305 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood cultures (BCs) performed
Number of subjects: 760
Study 10888712 — intervention group
Group type: EXPERIMENTAL
Intervention: leflunomide (loading dose 100 mg/day for 3 days, maintenance dose 20 mg/day)
Number of subjects: 999
Study 10888712 — intervention group
Group type: COMPARATOR
Intervention: methotrexate (10-15 mg/week)
Number of subjects: 999
Study 10888712 — intervention group
Group type: EXPERIMENTAL
Intervention: leflunomide
Number of subjects: 999
Study 10888712 — intervention group
Group type: COMPARATOR
Intervention: methotrexate
Number of subjects: 999
Study 9365968 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 50
Study 9365968 — intervention group
Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 50
Study 1526090 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 40‐5967 (150 mg)
Number of subjects: 64
Study 1526090 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 40‐5967 (200 mg)
Number of subjects: 64
Study 1526090 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 40‐5967 (50, 100, 150, 200 mg)
Number of subjects: 64
Study 1526090 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 40‐5967
Number of subjects: 64
Study 3549681 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (3 mg/kg/day)
Number of subjects: 10
Study 29958042 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone referral
Number of subjects: 959
Study 29958042 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine referral
Number of subjects: 959
Study 29958042 — intervention group
Group type: EXPERIMENTAL
Intervention: Training
Number of subjects: 959
Study 26227577 — intervention group
Group type: EXPERIMENTAL
Intervention: Partners for Change Outcome Management System (PCOMS) feedback scales
Number of subjects: 75
Study 26227577 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (no feedback scales)
Number of subjects: 75
Study 24030518 — intervention group
Group type: EXPERIMENTAL
Intervention: 10g gel-forming pectin
Number of subjects: 32
Study 24030518 — intervention group
Group type: COMPARATOR
Intervention: 3g gelatin and 2g starch (control)
Number of subjects: 32
Study 23160228 — intervention group
Group type: EXPERIMENTAL
Intervention: SYSADOA group chemicals administered orally for 13 weeks
Number of subjects: 34
Study 23160228 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 34
Study 20560030 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramyocardial BMMC injection
Number of subjects: 109
Study 20560030 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical therapy
Number of subjects: 109
Study 18630763 — intervention group
Group type: EXPERIMENTAL
Intervention: I.M ketoprofen (100 mg) + interpleural bupivacaine (0.4 ml/kg)
Number of subjects: 40
Study 18630763 — intervention group
Group type: COMPARATOR
Intervention: I.M pethidine (1.5 mg/kg)
Number of subjects: 40
Study 18630763 — intervention group
Group type: COMPARATOR
Intervention: I.M ketoprofen (100 mg)
Number of subjects: 40
Study 18630763 — intervention group
Group type: COMPARATOR
Intervention: interpleural bupivacaine (0.4 ml/kg)
Number of subjects: 40
Study 15714901 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcoholics
Number of subjects: 0
Study 15714901 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study 11834852 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional 2.5 mg/ml verapamil hydrochloride injections administered at timed intervals
Number of subjects: 0
Study 11834852 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving the same treatment except the verapamil hydrochloride
Number of subjects: 0
Study 11834852 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional 2.5 mg/ml verapamil hydrochloride injections
Number of subjects: 0
Study 10573445 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive stereotype reinforcement
Number of subjects: 47
Study 10573445 — intervention group
Group type: COMPARATOR
Intervention: Negative stereotype reinforcement
Number of subjects: 47
Study 8918275 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (75 mg once daily)
Number of subjects: 19185
Study 8918275 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (325 mg once daily)
Number of subjects: 19185
Study 8918275 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 19185
Study 8918275 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 19185
Study 2031046 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized terbutaline (5 mg inhaled 3 times daily) with PEP
Number of subjects: 10
Study 2031046 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized terbutaline (5 mg inhaled 3 times daily) without PEP
Number of subjects: 10
Study 2031046 — intervention group
Group type: COMPARATOR
Intervention: Placebo inhalations with PEP
Number of subjects: 10
Study 7216603 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (2 h/d on a bicycle ergometer)
Number of subjects: 3
Study 7216603 — intervention group
Group type: COMPARATOR
Intervention: No exercise (control condition)
Number of subjects: 3
Study 30321947 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C 500mg twice a day
Number of subjects: 0
Study 30321947 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablet twice a day
Number of subjects: 0
Study 28272250 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone IV-PCA (7.5 mg)
Number of subjects: 127
Study 28272250 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl IV-PCA (100 μg)
Number of subjects: 127
Study 26433318 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight control (review every 4 weeks, escalation of treatment if minimal disease activity criteria not met)
Number of subjects: 206
Study 26433318 — intervention group
Group type: COMPARATOR
Intervention: Standard care (standard therapy according to the treating clinician, review every 12 weeks)
Number of subjects: 206
Study 26433318 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight control
Number of subjects: 206
Study 26433318 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 206
Study 24158181 — intervention group
Group type: EXPERIMENTAL
Intervention: Attending biosketch card intervention
Number of subjects: 212
Study 24158181 — intervention group
Group type: COMPARATOR
Intervention: Control group (no biosketch card)
Number of subjects: 212
Study 22524296 — intervention group
Group type: EXPERIMENTAL
Intervention: High-value associations
Number of subjects: 0
Study 22524296 — intervention group
Group type: COMPARATOR
Intervention: Low-value associations
Number of subjects: 0
Study 22524296 — intervention group
Group type: EXPERIMENTAL
Intervention: Reward-related activation changes in dentate gyrus/CA(2,3) during encoding
Number of subjects: 0
Study 22524296 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional connectivity between dentate gyrus/CA(2,3) and dopaminergic midbrain
Number of subjects: 0
Study 22524296 — intervention group
Group type: EXPERIMENTAL
Intervention: High-value associations during retrieval
Number of subjects: 0
Study 19464025 — intervention group
Group type: EXPERIMENTAL
Intervention: Offer pacifier
Number of subjects: 1021
Study 19464025 — intervention group
Group type: COMPARATOR
Intervention: Not offer pacifier
Number of subjects: 1021
Study 17767451 — intervention group
Group type: EXPERIMENTAL
Intervention: CathRite system
Number of subjects: 38
Study 17767451 — intervention group
Group type: COMPARATOR
Intervention: Control (standard 'blind' technique)
Number of subjects: 38
Study 15084178 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab group (1 mg/kg daclizumab and 100 mg prednisolone for 3 days)
Number of subjects: 364
Study 15084178 — intervention group
Group type: COMPARATOR
Intervention: Control group (steroids tapered to 0 mg at week 16)
Number of subjects: 364
Study 15084178 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab group
Number of subjects: 364
Study 15084178 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 364
Study 11165423 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Dose Oral Alpha Interferon
Number of subjects: 0
Study 9884853 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron (2 mg)
Number of subjects: 842
Study 9884853 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (4 mg)
Number of subjects: 842
Study 9884853 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 842
Study 8004831 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil treatment for two years
Number of subjects: 106
Study 8004831 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension management with enalapril maleate
Number of subjects: 106
Study 8004831 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 106
Study 2680186 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 15
Study 2680186 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 380483 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 micron microaggregate filter
Number of subjects: 40
Study 380483 — intervention group
Group type: COMPARATOR
Intervention: 260 micron standard filter
Number of subjects: 40
Study 30225992 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 mg
Number of subjects: 0
Study 30225992 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg
Number of subjects: 0
Study 30225992 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28351782 — intervention group
Group type: EXPERIMENTAL
Intervention: FP/FOR (1000/40 μg)
Number of subjects: 225
Study 28351782 — intervention group
Group type: EXPERIMENTAL
Intervention: FP/FOR (500/20 μg)
Number of subjects: 225
Study 28351782 — intervention group
Group type: COMPARATOR
Intervention: FP/SAL (1000/100 μg)
Number of subjects: 225
Study 28351782 — intervention group
Group type: COMPARATOR
Intervention: 1 to 2 exacerbations in 12 months before phase 1
Number of subjects: 225
Study 26436207 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (four 5-minute inflations and deflations of a standard blood-pressure cuff on the upper arm)
Number of subjects: 1612
Study 26436207 — intervention group
Group type: COMPARATOR
Intervention: Sham conditioning (control group)
Number of subjects: 1612
Study 26436207 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning
Number of subjects: 1612
Study 26436207 — intervention group
Group type: COMPARATOR
Intervention: Remote ischemic preconditioning and Sham conditioning (control group)
Number of subjects: 1612
Study 24228894 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg/day of extended-release isosorbide mononitrate added to standard therapy, titrated to 60 mg/day at week 6 if blood pressure exceeded 140/90 mmHg
Number of subjects: 154
Study 24228894 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg/day of extended-release isosorbide mononitrate added to standard therapy
Number of subjects: 154
Study 24228894 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study 21129756 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (5 mg/kg)
Number of subjects: 106
Study 21129756 — intervention group
Group type: COMPARATOR
Intervention: IVIG (2 g/kg)
Number of subjects: 106
Study 19726593 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine supplementation (150 microg I daily for 28 weeks)
Number of subjects: 184
Study 19726593 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 184
Study 17879366 — intervention group
Group type: EXPERIMENTAL
Intervention: Telaprevir (750 mg oral doses every 8 hours)
Number of subjects: 20
Study 17879366 — intervention group
Group type: EXPERIMENTAL
Intervention: Telaprevir and peginterferon alfa-2a (telaprevir 750 mg every 8 hours and peginterferon alfa-2a 180 mug weekly subcutaneous injections)
Number of subjects: 20
Study 17879366 — intervention group
Group type: COMPARATOR
Intervention: Placebo and peginterferon alfa-2a
Number of subjects: 20
Study 16890357 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group (n=24) underwent conditioning with anaesthetic cream on one arm, followed by evaluation of pain intensity ratings.
Number of subjects: 40
Study 16890357 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=16) did not receive the conditioning treatment.
Number of subjects: 40
Study 14656614 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational self-management intervention
Number of subjects: 65